Natixis’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$287K Buy
2,282
+1,053
+86% +$132K ﹤0.01% 740
2025
Q1
$137K Sell
1,229
-256
-17% -$28.6K ﹤0.01% 745
2024
Q4
$203K Buy
1,485
+918
+162% +$125K ﹤0.01% 764
2024
Q3
$65.3K Sell
567
-572
-50% -$65.9K ﹤0.01% 758
2024
Q2
$157K Sell
1,139
-442
-28% -$60.9K ﹤0.01% 708
2024
Q1
$218K Sell
1,581
-323
-17% -$44.5K ﹤0.01% 686
2023
Q4
$251K Sell
1,904
-578
-23% -$76.2K ﹤0.01% 667
2023
Q3
$279K Sell
2,482
-19,944
-89% -$2.24M ﹤0.01% 667
2023
Q2
$2.11M Buy
22,426
+6,001
+37% +$566K 0.02% 406
2023
Q1
$1.66M Sell
16,425
-28,224
-63% -$2.86M 0.02% 432
2022
Q4
$5.33M Buy
+44,649
New +$5.33M 0.03% 341
2022
Q3
Sell
-2,122
Closed -$208K 1035
2022
Q2
$208K Sell
2,122
-1,129
-35% -$111K ﹤0.01% 973
2022
Q1
$305K Sell
3,251
-543
-14% -$50.9K ﹤0.01% 1058
2021
Q4
$323K Sell
3,794
-400
-10% -$34.1K ﹤0.01% 1121
2021
Q3
$402K Sell
4,194
-3,230
-44% -$310K ﹤0.01% 1050
2021
Q2
$723K Buy
+7,424
New +$723K ﹤0.01% 657
2021
Q1
Sell
-4,030
Closed -$386K 1145
2020
Q4
$386K Buy
+4,030
New +$386K ﹤0.01% 928
2020
Q3
Sell
-3,732
Closed -$455K 845
2020
Q2
$455K Buy
+3,732
New +$455K ﹤0.01% 626
2020
Q1
Sell
-6,121
Closed -$656K 823
2019
Q4
$656K Buy
+6,121
New +$656K ﹤0.01% 688
2019
Q2
Sell
-9,147
Closed -$783K 850
2019
Q1
$783K Sell
9,147
-4,101
-31% -$351K ﹤0.01% 616
2018
Q4
$946K Buy
13,248
+1,411
+12% +$101K 0.01% 523
2018
Q3
$1.46M Buy
+11,837
New +$1.46M 0.01% 524
2016
Q4
Sell
-13,424
Closed -$680K 900
2016
Q3
$680K Buy
13,424
+4,813
+56% +$244K 0.01% 385
2016
Q2
$391K Sell
8,611
-280
-3% -$12.7K 0.01% 345
2016
Q1
$352K Buy
8,891
+66
+0.7% +$2.61K 0.01% 270
2015
Q4
$499K Buy
+8,825
New +$499K 0.01% 233